Ask AI

Biomarker-Guided Immunotherapy Decisions in Early-Stage NSCLC

Text Module
Text Module Start Activity
This activity is available for 0.50 CME/CE credit(s).

Released: October 08, 2026

Expiration: April 07, 2027

See Activity Collection

Treatment of early-stage non-small-cell lung cancer (NSCLC) continues to evolve with biomarker-guided treatment selection and expanding neoadjuvant, adjuvant, and perioperative immunotherapy options. This text module examines the role of comprehensive biomarker testing, practical challenges that may delay testing and treatment decisions, and evidence from pivotal phase III trials to guide the selection and sequencing of immunotherapy for patients with resectable NSCLC.

Biomarker Testing and Immunotherapy in Early NSCLC

Pre Assessment

Assess your current knowledge and clinical approach before beginning your text module.
1.

How many people with non-small-cell lung cancer (NSCLC) do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

At minimum, which of the following should be assessed at diagnosis of stage II resectable NSCLC to inform approved perioperative treatment options?

4.

A 68-year-old man has resectable stage IIIA NSCLC, ECOG PS 0, PD-L1 tumor proportion score (TPS) 50%, and no actionable EGFR, ALK, or RET alterations. He is considered an appropriate surgical candidate by the multidisciplinary team.

Which treatment plan would be an appropriate choice for this patient?